A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Table of Contents BRIDGEBIO PHARMA, INC. Consolidated Statements of Operations (in thousands, except share and per share amounts) Years Ended December 31, Net product revenue$362,368 $2,884 $— License and services revenue128,322 218,849 9,303 Royalty revenue11,386 169 — Total revenues, net502,076 221,902 9,303 Operating costs and expenses: Cost of revenues: Cost of goods sold15,687 1,442 — Cost of license, services, and royalty revenue5,275 2,436 2,446 Total cost of revenues20,962 3,878 2,446 Research and development451,953 506,461 455,711 Selling, general and administrative531,225 288,931 150,590 Restructuring, impairment, and related charges21,347 15,605 7,926 Total operating costs and expenses1,025,487 814,875 616,673 Loss from operations(523,411)(592,973)(607,370) Other income (expense), net: Interest income19,854 17,249 18,038 Interest expense(53,103)(90,991)(81,289) Noncash interest expense on deferred royalty obligations (1)(125,138)(8,299)— Gain on deconsolidation of subsidiari
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 502M | 502M | - | - | - | - |
| Net Income | -725M | -725M | -536M | -643M | -481M | -563M |
| EPS | $-3.78 | $-3.78 | $-2.88 | $-3.95 | $-3.26 | $-3.90 |
| Free Cash Flow | -447M | -447M | -522M | -529M | -424M | -511M |
| ROIC | -44.2% | -55.9% | -64.5% | -111.2% | -82.2% | -56.9% |
| Gross Margin | 61.6% | 61.6% | - | - | - | - |
| Debt/Equity | 0.00 | -0.36 | -0.51 | -0.34 | -0.36 | -0.52 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -523M | -523M | -593M | -607M | -512M | -577M |
| Operating Margin | -104.2% | -104.2% | - | - | - | - |
| ROE | 0.0% | - | - | - | - | - |
| Shares Outstanding | 192M | 192M | 186M | 163M | 148M | 144M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | 502M | 502M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | 61.6% | 61.6% |
| R&D | 210M | 337M | 451M | 399M | 456M | 506M | 452M | 452M |
| SG&A | 94M | 146M | 192M | 143M | 151M | 289M | 531M | 531M |
| EBIT | -266M | -474M | -577M | -512M | -607M | -593M | -523M | -523M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | -104.2% | -104.2% |
| Net Income | -261M | -449M | -563M | -481M | -643M | -536M | -725M | -725M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -144.4% | -144.4% |
| Non-Recurring | 0 | 0 | 0 | 56M | 7.9M | 16M | 21M | 21M |
| Returns on Capital | ||||||||
| ROIC | -52.1% | -53.3% | -56.9% | -82.2% | -111.2% | -64.5% | -55.9% | -44.2% |
| ROE | -63.8% | -774.9% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| ROA | -41.3% | -63.8% | -55.5% | -77.2% | -117.7% | -58.3% | -78.1% | -77.4% |
| Cash Flow | ||||||||
| Op. Cash Flow | -254M | -400M | -498M | -419M | -528M | -521M | -446M | -446M |
| Free Cash Flow | -256M | -407M | -511M | -424M | -529M | -522M | -447M | -447M |
| Owner Earnings | -275M | -460M | -603M | -518M | -643M | -623M | -584M | -584M |
| CapEx | 2.6M | 7.5M | 13M | 4.8M | 1.3M | 933K | 1.1M | 1.1M |
| Maint. CapEx | 0 | 1.5M | 5.8M | 6.8M | 6.5M | 6.1M | 5.4M | 5.4M |
| Growth CapEx | N/A | 6.1M | 7.4M | 0 | 0 | 0 | 0 | 0 |
| D&A | 0 | 1.5M | 5.8M | 6.8M | 6.5M | 6.1M | 5.4M | 5.4M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 997K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 75M | 200M | 0 | 0 | 0 | 48M | 48M |
| Buyback Yield | N/A | 0.9% | 10.3% | N/A | N/A | N/A | 0.3% | 0.3% |
| Stock-Based Comp | 21M | 58M | 100M | 92M | 109M | 96M | 133M | 133M |
| Debt Repayment | 1.1M | 13M | 124M | 20M | 0 | 473M | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | -454M | -493M | -333M | 19M | -292M | 67M | 163M | 181M |
| Cash & Equiv. | 364M | 356M | 394M | 377M | 376M | 681M | 570M | 570M |
| Long-Term Debt | 92M | 92M | 431M | 431M | 446M | 739M | 741M | 741M |
| Debt/Equity | 0.22 | 1.97 | -0.52 | -0.36 | -0.34 | -0.51 | -0.36 | 0.00 |
| Interest Coverage | -30.4 | -12.9 | -12.3 | -6.4 | -7.5 | -17.3 | -4.2 | -4.2 |
| Equity | 408M | 58M | -870M | -1.3B | -1.4B | -1.5B | -2.1B | -2.1B |
| Total Assets | 632M | 704M | 1.0B | 623M | 546M | 919M | 936M | 936M |
| Total Liabilities | 156M | 596M | 1.9B | 1.9B | 1.9B | 2.4B | 3.0B | 3.0B |
| Intangibles | N/A | 0 | 45M | 29M | 26M | 24M | 28M | 28M |
| Retained Earnings | -440M | -889M | -1.4B | -1.9B | -2.6B | -3.1B | -3.8B | -3.8B |
| Working Capital | 508M | 547M | 754M | 427M | 334M | 566M | 510M | 510M |
| Current Assets | 569M | 643M | 889M | 549M | 478M | 721M | 798M | 798M |
| Current Liabilities | 60M | 96M | 135M | 121M | 144M | 154M | 288M | 288M |
| Per Share Data | ||||||||
| EPS | -2.48 | -3.80 | -3.90 | -3.26 | -3.95 | -2.88 | -3.78 | -3.78 |
| Owner EPS | -2.62 | -3.89 | -4.18 | -3.51 | -3.95 | -3.35 | -3.05 | -3.05 |
| Book Value | 3.89 | 0.49 | -6.03 | -8.50 | -8.32 | -7.89 | -10.88 | -10.88 |
| Cash Flow/Share | -2.41 | -3.38 | -3.45 | -2.84 | -3.24 | -2.80 | -2.33 | -3.75 |
| Dividends/Share | 0.01 | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 105.1M | 118.1M | 144.2M | 147.6M | 162.8M | 186.0M | 191.8M | 191.8M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -20.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 9.5 | 141.7 | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | 17.5 | 29.8 |
| FCF Yield | -6.6% | -5.0% | -26.4% | -42.7% | -7.8% | -10.0% | -3.1% | -3.0% |
| Market Cap | 3.9B | 8.2B | 1.9B | 995M | 6.8B | 5.2B | 14.5B | 14.9B |
| Avg. Price | 27.57 | 34.94 | 55.18 | 9.75 | 21.10 | 28.35 | 45.89 | 77.93 |
| Year-End Price | 36.84 | 69.48 | 13.43 | 6.74 | 41.81 | 27.99 | 75.80 | 77.93 |
BridgeBio Pharma, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 61.6%. Total shareholder yield (buybacks) is 0.3%.
BridgeBio Pharma, Inc. (BBIO) has a 5-year average return on invested capital (ROIC) of -74.1%. This is below average and may indicate limited pricing power.
BridgeBio Pharma, Inc. (BBIO) has a market capitalization of $14.9B. It is classified as a large-cap stock.
BridgeBio Pharma, Inc. (BBIO) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.32%.
BridgeBio Pharma, Inc. (BBIO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
BridgeBio Pharma, Inc. (BBIO) reported annual revenue of $502 million in its most recent fiscal year, based on SEC EDGAR filings.
BridgeBio Pharma, Inc. (BBIO) has a net profit margin of -144.4%. The company is currently unprofitable.
BridgeBio Pharma, Inc. (BBIO) generated $-447 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
BridgeBio Pharma, Inc. (BBIO) reported earnings per share (EPS) of $-3.78 in its most recent fiscal year.
BridgeBio Pharma, Inc. (BBIO) has a 5-year average gross margin of 61.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 7 years of financial data for BridgeBio Pharma, Inc. (BBIO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BridgeBio Pharma, Inc. (BBIO) has a book value per share of $-10.88, based on its most recent annual SEC filing.